Skip to main content
. 2021 Apr 14;129(4):047010. doi: 10.1289/EHP8054

Figure 1.

Figure 1A to 1C is a set of three stacked bar graphs titled Organophosphate Esters and Androgen Receptor Antagonism, Polybrominated diphenyl Ethers and Estrogen Receptor Agonism, and Polybrominated diphenyl Ethers and Thyroid Hormone Receptor Antagonism, respectively, plotting Geometric Means (percentage of Contribution), ranging from 0 to 100 in increments of 25 (y-axis) across Unweighted Concentrations of All in Chemical Class, Potency−Weighted Concentrations of Known ’Active’, and Concentrations of Those with Unknown Potency (x-axis), respectively. The data from the graph are as follows: Organophosphate Esters and Androgen Receptor Antagonism: Unweighted Concentrations of All in Chemical Class: Triphenyl phosphate: 4.22 percent, tris(1,3-dichloro-2-propyl) phosphate: 4.68 percent, Tris (1-chloro-2-propyl) phosphate: 20.7 percent, Tris(2-butoxyethyl) phosphate: 66.1 percent; Potency−Weighted Concentrations of Known ’Active’: 2-Ethylhexyl diphenyl phosphate: 5.86 percent, Cresyl Di Phenyl Phosphate: 9.91 percent, Triphenyl phosphate: 26.4 percent, tris(1,3-dichloro-2-propyl) phosphate: 52 percent; Concentrations of Those with Unknown Potency: Triphenylphosphine: 10.2 percent, Bisphenol A bis(diphenylphosphate): 18.2 percent, 2,2-bis(chloromethyl)trimethylene bis(bis(2-chloroethyl)phosphate): 20.3 percent, tris(2,4,6-trimethoxyphenyl)phosphine: 20.3 percent, and Resorcinol bis(diphenyl phosphate): 30.4 percent; Polybrominated diphenyl Ethers and Estrogen Receptor Agonism: Unweighted Concentrations of All in Chemical Class: Decabromodiphenyl ether–negative 47: 6.08 percent, Decabromodiphenyl ether: negative 99: 11.4 percent, Decabromodiphenyl ether–negative 209: 76.3 percent; Potency−Weighted Concentrations of Known ’Active’: Decabromodiphenyl ether–negative 47: 100 percent; and Concentrations of Those with Unknown Potency: Decabromodiphenyl ether–negative 209: 93.6 percent; and Polybrominated diphenyl Ethers and Thyroid Hormone Receptor Antagonism: Unweighted Concentrations of All in Chemical Class: Decabromodiphenyl ether–negative 47: 6.08 percent, Decabromodiphenyl ether–negative 99: 11.4 percent, Decabromodiphenyl ether–negative 209: 76.3 percent; Potency−Weighted Concentrations of Known ’Active’: Decabromodiphenyl ether–negative 47: 31.3 percent, Decabromodiphenyl ether–negative 99: 68.7 percent; and Concentrations of Those with Unknown Potency: Decabromodiphenyl ether–negative 209: 93.6 percent.

Comparison of profiles of chemicals with any vs. active vs. unknown designations for select pairs of assay end points and chemical classes, using Tox21 high-throughput screening data (Table 2) (Huang et al. 2016). (A) OPEs and androgen receptor antagonism, (B) PBDEs and estrogen receptor agonism, and (C) PBDEs and thyroid hormone receptor antagonism. Values below the limit of detection were replaced with half the limit. Unlabeled stacked bars represent chemicals that did not make appreciable contributions (<4%) to the geometric mean concentrations of that chemical class. Note: BDE-47, decabromodiphenyl ether–47; BDE-99, decabromodiphenyl ether–99; BDE-209, decabromodiphenyl ether–209; BDP, bisphenol A bis(diphenylphosphate); CDPP, cresyl di phenyl phosphate; EHDPP, 2-ethylhexyl diphenyl phosphate; OPEs, organophosphate esters; PBDEs, polybrominated diphenyl ethers; RDP, resorcinol bis(diphenyl phosphate); TBOEP, tris(2-butoxyethyl) phosphate; TCIPP, tris (1-chloro-2-propyl) phosphate; TDCIPP, tris(1,3-dichloro-2-propyl) phosphate; TMPP, tris(2,4,6-trimethoxyphenyl)phosphine; TPHP, triphenyl phosphate; TPP, triphenylphosphine; V6, 2,2-bis(chloromethyl)trimethylene bis(bis(2-chloroethyl)phosphate).